Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of LAT010 in Chinese patients with locally advanced or metastatic solid tumors
CTR20244740Phase 2Active
- Sponsor
- Reindeer Biotech
- Start
- Dec 2024
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of LAT010 in Nonhematologic neoplasms (7 arms), sponsored by Reindeer Biotech. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Dose-limiting toxicities and 2 more. Started Dec 2024; status: active.
02
Drugs
LAT010
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20244740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244740.